Emergent BioSolutions (EBS) announced that its Board of Directors has appointed Joseph Papa as president and CEO, effective February 21, 2024. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. Papa brings over 35 years of experience in the healthcare and pharmaceutical industry, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation (BLCO)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- EBS Upcoming Earnings Report: What to Expect?
- Emergent extending shelf-life of newly manufactured NARCAN, FDA says
- Emergent BioSolutions awarded procurement contract valued up to $235.8M
- Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
- Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)
